Mingliang Ji1,2, Shiyang Jiang1,2, Jun Zhao3,4, Xirun Wan1,2, Fengzhi Feng1,2, Tong Ren1,2, Junjun Yang1,2, Yang Xiang5,6. 1. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. 2. National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China. 3. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. zhaojun@pumch.cams.cn. 4. National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China. zhaojun@pumch.cams.cn. 5. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. xiangy@pumch.cn. 6. National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China. xiangy@pumch.cn.
Abstract
BACKGROUND: Guidelines recommend etoposide, methotrexate, actinomycin D (EMA)/cyclophosphamide, vincristine (CO) as first-line treatment for high-risk gestational trophoblastic neoplasia (GTN). However, the floxuridine, actinomycin D, etoposide and vincristine (FAEV) regimen is commonly used to treat these patients in China. We conducted a randomised controlled trial to compare the efficacies and toxicities of FAEV and EMA/CO. METHODS: Ninety-four patients with GTN were enrolled between May 2015 and April 2019 and randomly assigned to the FAEV or EMA/CO regimen. The rates of complete remission and relapse and the toxicities were compared in August 2021. RESULTS: Five patients were excluded from the analysis. There were 46 patients in the FAEV group and 43 patients in the EMA/CO group. The complete remission rates following primary treatment were 89.1% and 79.1% (P = 0.193), respectively. The relapse rates were 8.7% and 9.3% (P = 0.604). The apparent incidences of grade 4 myelosuppression were 60.9% and 32.6% (P = 0.008), respectively; however, they became both 32.6% (P = 0.996) after granulocyte colony-stimulating factor support. Other adverse reactions were similar in the two groups. No patient died of disease. CONCLUSION: FAEV has comparable efficacy and toxicity to EMA/CO as the primary treatment for high-risk GTN, and may thus be another first-line choice of chemotherapy. CLINICAL TRIAL REGISTRATION: chictr.org.cn: ChiCTR1800017423.
BACKGROUND: Guidelines recommend etoposide, methotrexate, actinomycin D (EMA)/cyclophosphamide, vincristine (CO) as first-line treatment for high-risk gestational trophoblastic neoplasia (GTN). However, the floxuridine, actinomycin D, etoposide and vincristine (FAEV) regimen is commonly used to treat these patients in China. We conducted a randomised controlled trial to compare the efficacies and toxicities of FAEV and EMA/CO. METHODS: Ninety-four patients with GTN were enrolled between May 2015 and April 2019 and randomly assigned to the FAEV or EMA/CO regimen. The rates of complete remission and relapse and the toxicities were compared in August 2021. RESULTS: Five patients were excluded from the analysis. There were 46 patients in the FAEV group and 43 patients in the EMA/CO group. The complete remission rates following primary treatment were 89.1% and 79.1% (P = 0.193), respectively. The relapse rates were 8.7% and 9.3% (P = 0.604). The apparent incidences of grade 4 myelosuppression were 60.9% and 32.6% (P = 0.008), respectively; however, they became both 32.6% (P = 0.996) after granulocyte colony-stimulating factor support. Other adverse reactions were similar in the two groups. No patient died of disease. CONCLUSION: FAEV has comparable efficacy and toxicity to EMA/CO as the primary treatment for high-risk GTN, and may thus be another first-line choice of chemotherapy. CLINICAL TRIAL REGISTRATION: chictr.org.cn: ChiCTR1800017423.
Authors: Kam Singh; Sarah Gillett; Jane Ireson; Anne Hills; John A Tidy; Robert E Coleman; Barry W Hancock; Matthew C Winter Journal: Int J Cancer Date: 2020-12-04 Impact factor: 7.396
Authors: Antonio Braga; Gabriela Paiva; Ehsan Ghorani; Fernanda Freitas; Luis Guillermo Coca Velarde; Baljeet Kaur; Nick Unsworth; Jingky Lozano-Kuehne; Ana Paula Vieira Dos Santos Esteves; Jorge Rezende Filho; Joffre Amim; Xianne Aguiar; Naveed Sarwar; Kevin M Elias; Neil S Horowitz; Ross S Berkowitz; Michael J Seckl Journal: Lancet Oncol Date: 2021-06-25 Impact factor: 41.316
Authors: Antonio Braga; Paulo Mora; Andréia Cristina de Melo; Angélica Nogueira-Rodrigues; Joffre Amim-Junior; Jorge Rezende-Filho; Michael J Seckl Journal: World J Clin Oncol Date: 2019-02-24
Authors: Alexandra K Isagulieva; Dmitry N Kaluzhny; Artemy D Beniaminov; Nataliya V Soshnikova; Alexander A Shtil Journal: Int J Mol Sci Date: 2022-08-09 Impact factor: 6.208